Due to its ability to modulate tau pathology in both aged AppNL–G–F and WT mice, B. breve MCC1274 is considered a potential therapeutic target for AD; however, further research is needed to confirm its efficacy in humans. Here, MAPT is linked to Alzheimer disease.